1. The binding of lead to human blood serum, and components of serum, was studied by titration with the addition of Pb(NO,), solution, monitoring the free Pb2+ concentration with a Pb2+ electrode, and by equilibrium dialysis.
INTRODUCTION
Lead is now distributed ubiquitously in biological systems, and poisoning still occurs in individuals occupationally or otherwise exposed to lead and its compounds. Many, if not all, of the toxic effects of lead correlate with its concentration in blood [l] . It is wellestablished that 99% of the lead in blood is bound to the erythrocytes, with about 1% found in plasma or serum at Correspondence: Dr T. J. B. Simons, Physiology Group, Biomedical Sciences Division, King's College London, Strand, London WC2R 2LS. blood lead concentrations below 2 ,umol/l [2, 3] . The percentage of lead found in plasma or serum rises steeply at blood concentrations above 2 prnol/l, which occur in cases of lead-induced neuropathy and plumbism [2, 31 . The chemical state of lead in blood plasma and interstitial fluid is of considerable interest because lead is transferred to these fluids after its absorption in the gut or lungs, and, whatever intermediate storage sites may be involved, is carried by them to its site of action, or to the kidneys for excretion. A trace metal ion could occur in four possible states: as part of a metalloprotein, bound with high affinity and only slowly dissociating; loosely bound to serum proteins, such as albumin; complexed to ligands of low M,, such as amino acids and other carboxylic acids; and as the free inorganic ion. The concentration of the last is likely to be a very small fraction of the total, but this concentration may be of special importance in determining the flux across membranes, binding and toxicity.
There are several specific metal-binding proteins in human serum. In addition to iron, transferrin has been reported to bind lead [4] as well as a number of other metal ions; a,-macroglobulin binds cadmium in addition to zinc [5, 61 . Albumin binds lead as well as many other metallic ions non-specifically [7] . A computer analysis of the binding 'of lead to low-M, compounds in plasma suggested that 80% of the lead not bound to protein binds to cysteine [8] . However, there is very little experimental evidence on either the normal chemical distribution of lead in serum or on the binding properties of the various putative ligands. The concentration of free lead ([Pb2+] ) in serum has not to our knowledge been estimated.
The present experiments were undertaken to answer some of the above questions. The methods used include titration of whole serum and some of its constituents in the presence of a Pb2+ electrode, equilibrium dialysis and chemical analysis. Serum, rather than plasma, was studied, because all of the agents we are aware of which may be added to blood to prevent clotting also have the property of binding lead. 
Measurement of PbZ+ binding by titration
Titrations were carried out with serum, dialysed serum or with a putative ligand for lead in a titration medium. The titration medium contained 90 mmol/l NaClO, and 20 mmol/l 4-( 2-hydroxyethy1)-1 -piperazine-sulphonic acid at pH 7.4. Lead was titrated by adding small volumes, 5-20 pl, of 1, 10 or 100 mmol/l Pb(NO,), to 6-8 ml of solution which was stirred magnetically at room temperature (25"C), and which contained the Pb2+-electrode assembly and a fine pH electrode. The meter was connected to a chart recorder so that the Pb2+-electrode potential could be monitored continuously. The pH was adjusted to 7.4, if necessary, by the addition of small volumes of HCIO, or NaOH. After each addition of Pb(NO,),, the electrode potential was followed until a stable reading was obtained. Values of total lead concentration ([Pb,]) and [Pb2 +I were calculated corresponding to each addition of Pb(NO,),, and were plotted against each other. A tracing of an original record, and the corresponding graph, are shown in Fig. 1 For seruni, human venous blood was centrifuged immediately after being taken. The plasma was trans-ferred to another tube, allowed to clot and recentrifuged. Chemical reactions with serum were carried out by allowing the reagents to act for 5 min at room temperature (25°C). Dialysis was performed in Visking tubing against an excess of titration medium at pH 7.4 for 48 h at 4°C. The research programme had been approved by the local ethical committee.
Total protein in serum was estimated by the method of Goa [13] .
Equilibrium dialysis
One millilitre of dialysed serum, albumin (50 g/l) or transferrin (50 pmol/I) in titration medium (above) in a Visking sac was dialysed against 10 ml of medium at pH 7.4 containing a lead buffer [15, 30 or 60 pmoI/l Pb(NO,), together with 100 pmol/l Tiron ( 1,2-dihydroxybenzene-3,5-disulphonate)] and added 203Pb. The external medium was mixed magnetically at room temperature for 48 h. Samples from the external fluid were taken after the first 24 h of dialysis for comparison with the final samples. The binding of lead to the protein in the Visking sac was estimated from the difference between the concentration of 203Pb counts inside and outside the sac. This was related to the external [Pb2+] measured with the electrode.
Determination of cysteine and cystine in serum
Chemical method. Fresh serum was deproteinized with 6.4% (w/v) perchloric acid. Portions of supernatant were analysed for free cysteine and 'total' cysteine
) by the acid ninhydrin method H.p.1.c. method. Samples of serum (1 ml), or 100 pmol/l cysteine or carboxymethylcysteine (standards) were deproteinized by the addition of 0.1 ml of trichloroacetic acid (500 g/l). After centrifuging, 0.25 ml of supernatant was mixed with 0.2 ml of Na,CO, solution (100 g/I), 0.1 ml of water and 0.05 pl of iodoacetic acid solution (0.5 mol/I) and allowed to stand at room temperature for 20 min. This converted free cysteine to carboxymethylcysteine. In order to measure 'total' cysteine (as above), 0.25 ml of supernatant was mixed with 0.2 ml of Na,CO, solution (100 g/l) and 0.1 ml of dithiothreitol solution (10 g/l) and incubated at 37°C for 30 min. After cooling, the solution was allowed to react with iodoacetic acid solution in the same way.
The h.p.1.c. used two buffers: (A) 0.1 mol/l sodium acetate with 5% (w/v) tetrahydrofuran, adjusted to pH 7.2 with acetic acid, and (B) methanol containing 5% (w/v) tetrahydrofuran. Separation was carried out on a 50 mm x 4.6 mm column of Spherisorb 5 ODs, preceded by a similar guard column containing Spherisorb 10 ODs, at a flow rate of 1 ml/min and a starting pressure 1.4 x lo7 Nm-, at room temperature. Portions of neutralized carboxymethylated materials were made fluorescent by reaction with o-phthalaldehyde reagent (Fluoroaldehyde, Pierce), injected on to the column, and were separated initially by isocratic flow with 95% buffer A/5% buffer B ~4 1 . for 7 min, followed by linear gradient flow up to 20% buffer A/80% buffer B over 10 min. Peak heights and areas were determined with an LDC Milton Roy C1-1OB Integrator.
RESULTS

Binding of lead to serum and modified serum
Fresh and modified human serum were titrated with lead. A sample titration is shown in Fig. 1 Table 1 . Serum was allowed to stand in air for 6 h, and it was dialysed against control medium for 48 h, to remove low-M, components (in this case the protein concentration was measured). Both these treatments resulted in the loss of about 60% of the lead-binding property of serum. An experiment to measure the binding of lead to serum by equilibrium dialysis is presented in Fig. 2 . Serum was also treated with a number of proteinmodifying reagents: 5 rnmol/l N-ethyl maleimide (NEM) (which reacts with thiol groups), 100 mmol/l I-cyclohexyl-3-(2-morpholinoethyl)carbodi-imide methop-toluenesulphonate (CMC) plus 1 mol/l glycine methyl ester (GME) (which react with carboxylate and thiol groups), 1 mmol/l diethylpyrocarbonate (which reacts with histidine residues) and 80 mmol/l acetic anhydride (which reacts with amine groups). These also led to the 
loss of 60-70% of the lead binding property of serum, apart from diethyl pyrocarbonate, which had no effect.
B
*The value for cysteine was derived from 3-14 measurements at each of six lower concentrations (see Fig. 2 ).
Binding of lead to non-protein components of serum
The binding of lead to a number of components or putative components of serum was examined by titration, in order to determine whether this binding was sufficiently large to account for the observed binding of lead to serum. Apart from proteins, the molecules were all tested at a concentration of 1 mmol/l. Binding of lead was insignificant ( a less than twice the value in control medium) with creatinine, cystine, glutamate, glutamine, glycine, lactate, methionine, sodium bicarbonate and urate. Table 2 gives the values of p for molecules which did show significant lead binding. Cysteine was the most effective agent for the binding of lead. It bound lead so strongly that the value of j3 at a concentration of 1 mmol/l could not be measured directly, but was extrapolated from observations at lower concentrations (Fig. 3) . There was also significant binding to other molecules possessing a free thiol group.
Binding of lead to plasma proteins
The binding of lead to (bovine) serum albumin was assessed by titration, whereas its possible binding to transferrin was assessed by titration and by equilibrium dialysis. Solutions of bovine serum albumin in control medium (50 g/l) bound lead with a weighted average slope (j3) of 1276 k 8 ( n = 5). By contrast, the binding of lead to transferrin (5 g/l, 64 pmol/l) was negligible (j3 = 4). As a check, the binding of lead to transferrin (3.9 g/l, 50 pmol/l), to albumin (50 g/l) and to serum was assessed by equilibrium dialysis, in the presence of Tiron, to maintain [Pb2+] in the range 10-8-10-7 mol/l. The results are given in Fig. 2 
Further observations on the binding of lead to cysteine
The thiol group on cysteine is unstable in aqueous solutions exposed to air, because of aerial oxidation. This is accompanied by the loss of lead-binding capacity. In two experiments with 100 pmol/l cysteine solutions in control buffer, lead binding (B) fell to 18% and 43% of the initial value after 90 min, and it fell to zero after 24 h. Experiments with cysteine were usually carried out with freshly made-up solutions to minimize losses, but even then there was probably some loss of cysteine. A graph of B against [cysteine] shows a positive intercept on the abscissa, corresponding to a loss of about 10 pmol/l cysteine (Fig. 3) .
Reaction of the thiol group on cysteine with 5 mmol/l NEM also brought about the abolition of lead binding (not shown).
The binding of lead to cysteine was also examined for mixtures of cysteine and albumin (Fig. 4) , and cysteine and serum (Fig. 5) . The binding of lead to 100 pmol/l cysteine alone was greater than to either albumin (10 g/l) or serum. In both cases the binding of lead to the mixture of cysteine with albumin or serum was intermediate between that to albumin or serum alone, and that to cysteine. This implies the loss of lead-binding capacity, which might be caused by aerial oxidation of cysteine or a thiol-exchange reaction. Curve-fitting to the data for the cysteine mixtures suggested that only 12% of the cysteine was effective in binding lead 20 min after mixing with albumin (Fig. 4) , whereas 52% was effective 5 min after mixing with serum, and 20% 30 min after mixing with serum (Fig. 5) .
Analysis of cysteine and cystine in serum
The concentrations of cysteine and cystine were measured in acid extracts of serum, using chemical analysis and h.p.1.c. The results (Table 3 ) are in good agreement with each other. These measurements exclude protein-bound cysteine, which would have been precipitated by the acid extraction procedure.
DISCUSSION
Technical aspects
Some comment on the titration method for measuring lead binding seems appropriate. mol/l for cysteine, serum and albumin, respectively. For cysteine and albumin, the observations can readily be fitted to a model for lead binding. Serum, however, might contain putative substances with a K , for Pb2+ of lo-'" mol/l or lower. If these substances were already saturated with lead, they would not bind additional lead during the titration, and would be undetectable. The amount of such substances would not be more than the lead content of fresh serum, about 0.1 1 k 0.05 ,ug/dl [3] or 5 x lo-' mol/l lead.
The results also show that when the Pb2+ electrode is placed in a nominally lead-free solution, it initially gives a spuriously high reading for [Pb2+]. In Figs. 1( b) , 4, and 5, the graph of [Pb,] against [Pb2+] has a positive intercept on the abscissa, at around 1 nmol/l for serum, 7 nmol/l for albumin and 0.03 nmol/l for cysteine solutions. This effect depends upon the lead-binding power of the solution, the discrepancy from zero being smaller for strong chelating agents. It has previously been discussed for the Ca2+ electrode [15] . This initial high reading does not seem to interfere with the subsequent measurement of lead binding during a titration. Extensive studies with cysteine solutions (Fig. 3) give a value for the Pb2+-cysteine K , at pH 7.4 that is in very close agreement with recent literature ( Table 2 ). The titration method can also be compared with equilibrium dialysis. The binding of lead to serum by dialysis is roughly linear in [Pb2+] with a slope of ( p ) of 897 t-55 (Fig. 2) . This is smaller than the value reported for dialysed serum in Table 1 (2006 k 14) .
The explanation seems to be that the binding of lead to dialysed serum shows significant curvature in the [Pb2+] range from 0 to 100 nmol/l, which is not apparent from Fig. 2 . The value of / 3 in Table 1 Observations of this sort should, in turn, help to explain the overall distribution of lead in the body and help to define mechanisms of toxicity. The state of lead in serum bears on its toxicity since the serum lead concentration does not rise much above 0.1 pg/dl until the total blood lead concentration exceeds 50 pg/dl. Beyond this, when clinical symptoms become apparent, the serum lead concentration rises steeply with increasing blood lead concentration [3] .
Lead-binding components of serum Sixty percent of the lead-binding ability of serum, as indicated by the value of p, is destroyed by standing in air, dialysis or treatment with NEM or acetic anhydride. This points to the involvement of a molecule containing a labile -SH group. It need not necessarily be dialysable, because it would be destroyed during 48 h of dialysis in contact with air. [There does appear, however, to be some NEMsensitive material in dialysed serum ( Table 2 ).] We know of four dialysable components of serum containing a free -SH group: cysteine, ergothioneine, glutathione and homocysteine. Of these, only cysteine and homocysteine bind lead sufficiently strongly to be serious candidates ( Table 2) . A cysteine concentration of 15 ,umol/l, or alternatively 300 ,umol/l homocysteine, would be needed to account for a / 3 of 3000, equivalent to the change in a caused by dialysis of serum or treatment with NEM. We found the free cysteine concentration in serum to be 8 pmol/l (Table 3) , whereas the total homocysteine concentration in plasma (including protein-bound and oxidized forms) is reported to be 10-13 ,mnol/l [16] . Thus there are insufficient free -SH groups to explain the observed binding. Furthermore, cysteine has a K , for Pb2+ of 5 nmol/l. This leads to a pronounced curvature of the titration graph in the 1-10 nmol/l range (Figs. 4 and 5) , which is not seen in the titration of serum (Figs. 1 and 5) , although it would have been expected. Compounds con-taining -SH groups are present in plasma in a variety of forms: as the free molecule, as the disulphide, as mixed disulphides, and bound to protein, either via a disulphide bond or by other means . Addition of one -SHcontaining molecule can displace another -SH compound from its disulphide or protein-bound form [17] . The binding of lead to cysteine might result in the displacement of bound cysteine by other molecules containing free -SH groups. Alternatively, lead might bind to proteinbound cysteine, as well as to free cysteine. The first suggestion would be limited by the low concentrations of non-cysteine free -SH groups in plasma: about 2 pmol/l glutathione [18] and below 3 pmol/l homocysteine [16, 191 . The second suggestion is purely hypothetical. There are substantial amounts of protein-bound cysteine in plasma (2.3k0.2 pmol/g of protein) [19] , of which an unknown proportion is bound by a disulphide bond, and hence is unavailable to bind lead.
About 40% of the lead-binding ability of serum is insensitive to NEM, dialysis or oxidation. This appears to be largely binding to protein, particularly albumin. The value for /3 in dialysed serum is 2006 f 14 ( Table 1) . On average these samples contained 78 k 3 g protein/l. /3 for bovine serum albumin (50 g/l) was 1276 iz 8. Thus if all the serum protein were bovine serum albumin, one would predict /3= 1276 x 78/50 = 1991 iz 78, in good agreement with the observed value. Apart from the obvious fact that serum contains a mixture of proteins, the titration graph of albumin is linear over the range of [Pb2+] from 10 to 100 nmol/l (Fig. 4) , whereas that for dialysed serum shows curvature, with lower values of /3 when observations above 10 nmol/l [Pb2+] are included (discussed above). This may be due to a minor component of serum with a relatively high affinity for Pb2+, whose identity remains uncertain. Our observations show that transferrin is unable to bind lead in the requisite manner, but there are several other proteins that we were unable to test, such as a,-macroglobulin.
